Cardiomyopathy, Hypertrophic
"Cardiomyopathy, Hypertrophic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
MeSH Number(s)
C14.280.238.100
C14.280.484.150.070.160
Concept/Terms
Cardiomyopathy, Hypertrophic- Cardiomyopathy, Hypertrophic
- Cardiomyopathies, Hypertrophic
- Hypertrophic Cardiomyopathies
- Hypertrophic Cardiomyopathy
- Cardiomyopathy, Hypertrophic Obstructive
- Cardiomyopathies, Hypertrophic Obstructive
- Hypertrophic Obstructive Cardiomyopathies
- Hypertrophic Obstructive Cardiomyopathy
- Obstructive Cardiomyopathies, Hypertrophic
- Obstructive Cardiomyopathy, Hypertrophic
Idiopathic Hypertrophic Subaortic Stenosis- Idiopathic Hypertrophic Subaortic Stenosis
- IHSS
- IHSSs
- Subvalvular Stenosis, Idiopathic Hypertrophic
- Hypertrophic Cardiomyopathy, Idiopathic
- Cardiomyopathies, Idiopathic Hypertrophic
- Cardiomyopathy, Idiopathic Hypertrophic
- Hypertrophic Cardiomyopathies, Idiopathic
- Idiopathic Hypertrophic Cardiomyopathies
- Idiopathic Hypertrophic Cardiomyopathy
- Hypertrophic Obstructive Cardiomyopathy (HOCM)
- Cardiomyopathies, Hypertrophic Obstructive (HOCM)
- Cardiomyopathy, Hypertrophic Obstructive (HOCM)
- Hypertrophic Obstructive Cardiomyopathies (HOCM)
- Idiopathic Hypertrophic Subvalvular Stenosis
- Idiopathic Hypertrophic Subaortic Stenosis (IHSS)
Asymmetric Septal Hypertrophy- Asymmetric Septal Hypertrophy
- Asymmetric Septal Hypertrophies
- Hypertrophies, Asymmetric Septal
- Hypertrophy, Asymmetric Septal
- Septal Hypertrophies, Asymmetric
- Septal Hypertrophy, Asymmetric
Below are MeSH descriptors whose meaning is more general than "Cardiomyopathy, Hypertrophic".
Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathy, Hypertrophic".
This graph shows the total number of publications written about "Cardiomyopathy, Hypertrophic" by people in Harvard Catalyst Profiles by year, and whether "Cardiomyopathy, Hypertrophic" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 6 | 1 | 7 |
| 1994 | 8 | 1 | 9 |
| 1995 | 9 | 0 | 9 |
| 1996 | 3 | 1 | 4 |
| 1997 | 8 | 0 | 8 |
| 1998 | 8 | 1 | 9 |
| 1999 | 7 | 2 | 9 |
| 2000 | 5 | 0 | 5 |
| 2001 | 3 | 2 | 5 |
| 2002 | 11 | 2 | 13 |
| 2003 | 5 | 1 | 6 |
| 2004 | 5 | 3 | 8 |
| 2005 | 14 | 2 | 16 |
| 2006 | 16 | 1 | 17 |
| 2007 | 9 | 1 | 10 |
| 2008 | 18 | 3 | 21 |
| 2009 | 15 | 2 | 17 |
| 2010 | 25 | 0 | 25 |
| 2011 | 24 | 1 | 25 |
| 2012 | 20 | 6 | 26 |
| 2013 | 11 | 3 | 14 |
| 2014 | 29 | 3 | 32 |
| 2015 | 15 | 0 | 15 |
| 2016 | 20 | 2 | 22 |
| 2017 | 23 | 3 | 26 |
| 2018 | 29 | 0 | 29 |
| 2019 | 24 | 1 | 25 |
| 2020 | 35 | 5 | 40 |
| 2021 | 42 | 1 | 43 |
| 2022 | 28 | 1 | 29 |
| 2023 | 5 | 0 | 5 |
Below are the most recent publications written about "Cardiomyopathy, Hypertrophic" by people in Profiles.
-
Multi-Omics Profiling of Hypertrophic Cardiomyopathy Reveals Altered Mechanisms in Mitochondrial Dynamics and Excitation-Contraction Coupling. Int J Mol Sci. 2023 Mar 01; 24(5).
-
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat Med. 2023 02; 29(2):412-421.
-
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Eur J Heart Fail. 2023 02; 25(2):260-270.
-
Genome-Wide Analysis of Left Ventricular Maximum Wall Thickness in the UK Biobank Cohort Reveals a Shared Genetic Background With Hypertrophic Cardiomyopathy. Circ Genom Precis Med. 2023 02; 16(1):e003716.
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023 01 03; 81(1):34-45.
-
Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy. Sci Rep. 2022 12 28; 12(1):22501.
-
Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy. Heart. 2022 10 28; 108(22):1807-1814.
-
Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy With Pulmonary Hypertension. Chest. 2023 Mar; 163(3):678-686.
-
Prediction of Major Adverse Cardiovascular Events in Patients With Hypertrophic Cardiomyopathy Using Proteomics Profiling. Circ Genom Precis Med. 2022 12; 15(6):e003546.
-
Machine learning evaluation of LV outflow obstruction in hypertrophic cardiomyopathy using three-chamber cardiovascular magnetic resonance. Int J Cardiovasc Imaging. 2022 Dec; 38(12):2695-2705.